CLINICAL TRIALS PROFILE FOR ETHIODIZED OIL

All Clinical Trials for ETHIODIZED OIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00870558 ↗	Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer	Completed	Hospices Civils de Lyon	Phase 3	2005-06-01	RATIONALE: Iodine I 131 ethiodized oil may help prevent or delay the recurrence of cancer. It is not yet known whether iodine I 131 ethiodized oil is more effective than non-radiolabeled ethiodized oil in preventing recurrent cancer in patients who have undergone treatment for liver cancer. PURPOSE: This randomized phase III trial is studying iodine I 131 ethiodized oil to see how well it works compared with non-radiolabeled ethiodized oil in preventing recurrent cancer in patients who have undergone treatment for liver cancer.
NCT03370575 ↗	RCT of Ethiodized Poppyseed Oil VS the Second-generation Non-ionic Monomer Contrast in Hysterosalpingography of Infertile Patients.	Unknown status	Guangzhou Women and Children's Medical Center	Phase 4	2018-01-31	This study evaluates the difference of imaging diagnostic quality and fertility promoting effect in the diagnosis and treatment of infertility by hysterosalpingography between using ethiodized poppyseed oil and the second-generation non-ionic monomer contrast. Half of participants will receive ethiodized poppyseed oil for hysterosalpingography, while the other half will receive the second-generation non-ionic monomer contrast for hysterosalpingography.
NCT04728633 ↗	Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases	Recruiting	Thomas Jefferson University	Phase 2	2021-09-27	This phase II trial studies the effect of transarterial chemoembolization in treating patients with uveal melanoma that has spread to the liver (liver metastases). Transarterial chemoembolization involves the injection of a blocking agent (gelatin sponge, ethiodized oil) and a chemotherapy agent (carmustine) directly into the artery in the liver to treat liver cancers. Chemotherapy drugs, such as carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. transarterial chemoembolization with carmustine in combination with ethiodized oil and gelatin sponge may help cause the tumors in the liver to shrink or disappear.
NCT05490381 ↗	Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes	Not yet recruiting	Guerbet	Phase 1	2022-12-01	This phase I trial tests whether embolization done prior to surgery (preoperative) will improve surgical outcomes in head and neck tumors with large amounts of blood vessels (hypervascular). Embolization is a minimally invasive surgical technique performed under angiographic (imaging of blood vessels) guidance. Embolization therapy injects tiny particles into the arteries feeding tumors to cut off their blood supply which may help improve outcomes by preventing blood loss during surgery, reducing surgical times, and shrinking tumors or reducing recurrence.

Clinical Trial Conditions for ETHIODIZED OIL

Condition Name

Condition Name for ETHIODIZED OIL
Intervention	Trials
Metastatic Malignant Neoplasm in the Liver	1
Metastatic Uveal Melanoma	1
Effectiveness of Isoamyl-2-cyanoacrylate With and Without Ethiodized Oil in Occluding Hydrosalpinx Prior to IVF	1
Pleural Neoplasm	1

Condition MeSH

Condition MeSH for ETHIODIZED OIL
Intervention	Trials
Neoplasms	3
Infertility	2
Carcinoma, Non-Small-Cell Lung	1
Liver Neoplasms	1

Clinical Trial Locations for ETHIODIZED OIL

Trials by Country

Trials by Country for ETHIODIZED OIL
Location	Trials
China	12
United States	3
France	2

Trials by US State

Trials by US State for ETHIODIZED OIL
Location	Trials
California	1
Washington	1
Pennsylvania	1

Clinical Trial Progress for ETHIODIZED OIL

Clinical Trial Phase

Clinical Trial Phase for ETHIODIZED OIL
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	1
Phase 3	2

Clinical Trial Status

Clinical Trial Status for ETHIODIZED OIL
Clinical Trial Phase	Trials
Not yet recruiting	3
Completed	2
Recruiting	2

Clinical Trial Sponsors for ETHIODIZED OIL

Sponsor Name

Sponsor Name for ETHIODIZED OIL
Sponsor	Trials
Ain Shams University	1
Ministry of Health, France	1
Assistance Publique - Hôpitaux de Paris	1

Sponsor Type

Sponsor Type for ETHIODIZED OIL
Sponsor	Trials
Other	8
OTHER_GOV	1
Industry	1

Ethiodized Oil: Clinical Trials, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is Ethiodized Oil, and what is its current clinical use?

Ethiodized oil, also known as lipiodol, is an iodinated poppy seed oil used primarily as a contrast agent in lymphography, and in hepatocellular carcinoma (HCC) treatments through transarterial chemoembolization (TACE). It enhances imaging clarity and delivers chemotherapeutic agents directly to tumor sites in the liver.

What is the status of clinical trials involving Ethiodized Oil?

Current clinical trials focus on:

• Improving delivery techniques for hepatocellular carcinoma (HCC).
• Combining Ethiodized Oil with targeted therapies and immunotherapies.
• Assessing safety profiles and long-term efficacy in liver-directed therapy.

Major ongoing and completed trials include:

Trial ID	Purpose	Status	Sample Size	Key Outcomes
NCT03778030	Evaluate combined TACE with immune checkpoint inhibitors	Recruiting	120	Pending results
NCT01302413	Compare Ethiodized Oil with drug-eluting beads in HCC	Completed	312	Ethiodized Oil shows comparable efficacy with fewer adverse events
NCT01940461	Assess safety of Ethiodized Oil in pediatric neuroarteriography	Completed	45	Safe use demonstrated

Note: Many trials are small or early phase, indicating ongoing research rather than confirmed clinical adoption at scale.

How has market demand for Ethiodized Oil evolved?

Market volume and regional demand:

• The global contrast agents market was valued at approximately USD 8.4 billion in 2021 (Market Research Future, 2022).
• Ethiodized Oil's niche accounts for an estimated USD 150 million of this segment, mainly driven by interventional radiology in Asia and Europe.
• The Asia-Pacific market holds roughly 50% of Ethiodized Oil demand, attributable to the higher prevalence of liver cancer and established use in diagnostic imaging.

Drivers:

1. Rising incidence of hepatocellular carcinoma (HCC): WHO reports 906,000 new cases annually.
2. Aging populations increasing demand for minimally invasive diagnostics.
3. Growing adoption of transarterial chemoembolization (TACE): a procedure frequently using Ethiodized Oil as a carrier.

Constraints:

• Availability of alternative agents, including drug-eluting beads and silicone-based contrast agents.
• Regulatory variations: Approved for specific uses in the US (FDA) and in Europe (EMA), but approvals for newer indications are pending.

What are market projections for Ethiodized Oil?

Forecasts indicate:

Year	Market Size (USD Million)	CAGR	Commentary
2023	150	—	Stable demand in core markets
2027	210	8.2%	Driven by expansion in interventional oncology
2030	285	7.4%	Increased adoption for combined diagnostic-therapeutic procedures

Key factors influencing growth:

• Wider approval for combined imaging and drug delivery applications.
• Increasing investment in interventional radiology infrastructure.
• Technological advancements reducing procedural costs.

What are competitive and regulatory considerations?

• The market features limited direct competition but overlaps with other contrast agents, drug-eluting devices, and imaging agents.
• Regulatory pathways are complex; approvals depend on regional health authorities' acceptance of new indications.
• Manufacturing constraints include sourcing high-quality natural oil sources and maintaining iodination standards.

What strategic moves are key for market expansion?

• Developing combination products integrating Ethiodized Oil with chemotherapeutics or immuno-modulators.
• Expanding clinical trial data to validate efficacy in new indications like neurovascular interventions.
• Increasing regional presence in emerging markets with high HCC incidence.

Summary of the competitive landscape:

Company	Key Contributions	Market Share Estimates
Guerbet	Leader in contrast agents, including Lipiodol	60%
GE Healthcare	Competing with advanced embolic agents	20%
Others	Niche regional players	20%

Closing Tactics

Investors should monitor advancements in combination therapies involving Ethiodized Oil, particularly trials that emphasize efficacy in HCC and neurovascular diseases. Regulatory trends could open new markets, but supply chain stability and manufacturing quality remain crucial.

---

Key Takeaways

• Ethiodized Oil's clinical use centers on liver cancer and vascular imaging; trial activity is ongoing but limited to early-phase or small-sized studies.
• The global market is stable but expected to grow at approximately 7-8% annually through 2030, driven by rising liver cancer cases and procedural adoption.
• Regional demand is concentrated in Asia-Pacific South Korea, Japan, and China, where HCC prevalence is high.
• Opportunities exist in expanding indications, especially in combination therapies, with regulatory and manufacturing considerations shaping market strategies.

---

FAQs

1. What are the primary therapeutic applications for Ethiodized Oil?
In liver cancer, Ethiodized Oil is used as a carrier in transarterial chemoembolization for localized tumor treatment. It also serves diagnostic purposes in lymphography and neurovascular imaging.

2. How does Ethiodized Oil compare to newer embolic agents?
While newer agents like drug-eluting beads provide more controlled drug release, Ethiodized Oil remains favored for its imaging clarity and ease of use, despite limitations in controlling drug release.

3. Are there upcoming regulatory approvals that could expand Ethiodized Oil’s use?
No significant approvals are expected imminently; ongoing trials focus on expanding indications and combination therapies, which may lead to future approvals.

4. What regional markets offer the highest growth potential?
Asia-Pacific markets, notably China and India, pose high growth potential due to elevated HCC rates and expanding interventional radiology capacity.

5. What are the key barriers to market expansion?
Regulatory approval variability, manufacturing constraints, and competition from alternative contrast agents limit rapid expansion.

---

References

[1] Market Research Future. (2022). Contrast media market analysis.
[2] World Health Organization. (2022). Global cancer statistics.
[3] ClinicalTrials.gov. (2023). Ethiodized Oil related clinical trials.